FDA Grants Nivolumab Breakthrough Designation for Head and
Neck Cancer
Published Online:
Monday, Apr 25, 2016
The FDA has granted a breakthrough therapy designation to nivolumab (Opdivo) as a
treatment for patients with recurrent or metastatic squamous cell carcinoma of the head
and neck (SCCHN) following a platinum-based therapy, according to the developer of
the PD-1 inhibitor Bristol-Myers Squibb
The FDA is expected to act on the review by Nov. 11, 2016, according to a
from Bristol-Myers Squib, makers of nivolumab.
19 Apr 2016
